



UNIQUE JOURNAL OF PHARMACEUTICAL AND BIOLOGICAL SCIENCES

Research Article

FORMULATION AND EVALUATION OF MATRIX SYSTEM FOR SIMULTANEOUS SUSTAINED RELEASE OF DICLOFENAC SODIUM AND TIZANIDINE HYDROCHLORIDE

Jobin Abraham*, Prafull Firodiya, Neeta Rai

Department of Pharmaceutics SIRT College of Pharmacy, Bhopal, M.P, INDIA

*Corresponding Author: **Jobin Abraham**

Department of Pharmaceutics SIRT College of Pharmacy, Bhopal, M.P, INDIA

Email: jobinabraham84@gmail.com

Received 03-06-2013; Revised 29-06-2013; Accepted 10-07-2013

ABSTRACT

In the present study, matrix tablets were formulated such as sustaining layer .sustained release layer was prepared by using synthetic polymer like ethyl cellulose by wet granulation method. The tablets were evaluated for Physico-Chemical Properties such as Hardness, Friability, Thickness Weight variation, Drug content uniformity. The In vitro release studies were performed in 0.1 N HCl for first two hr and in 6.8 pH Phosphate buffer upto 12 hr. It was observed that matrix tablets having formulation code F1-F12 which contained 50% ethyl cellulose were successfully sustained the release of drug upto 12hr. FT-IR studies revealed that there was no interaction between the drug and polymer used in the study.

Keywords: DICS-diclofenac sodium, TIZH-tizanidine hydrochloride Sustained release, Ethyl cellulose.

INTRODUCTION

All the pharmaceutical products formulated for systemic delivery via the oral route of administration irrespective of the mode of delivery (immediate, sustained or controlled release) and the design of dosage forms (either solid dispersion or liquid) must be developed within the intrinsic characteristics of gastrointestinal physiology, pharmacokinetics and pharmacodynamics as formulation design is essential to achieve a systemic approach to the successful development of an oral dosage form¹.

To define matrix, it is necessary to know the characters that differentiate it from other controlled release dosage forms².

- The physical state of drug.
- The matrix shape and alteration in volume as a function of time.
- The route of administration.
- The release kinetic model.

DICS and TIZH have been used in combination because there are minor differences in the pharmacokinetics of both the drugs. These two drugs are commonly prescribed by the doctors for the relief of pain and inflammations. Sustained release formulation of DICS and TIZH will be able to prolong the release of the both the drugs and reduce the fluctuations in

plasma drug concentrations as in case of conventional dosage form will thus minimize or prevent plasma peak-related adverse events and allow prolongation of the dosing interval enabling a once or twice daily administration with inherent benefits in terms of patient compliance. Sustained-release oral delivery systems are designed to achieve therapeutically effective concentrations of drug in the systemic circulation over an extended period of time, thus achieving better patient compliance and allowing a reduction of both the total dose of drug administered and the incidence of adverse side effects. Among the different approaches studied with this aim, matrix systems appears as one of the most attractive; from both the economic, as well as, process development and scale-up point of view³.

MATERIALS AND METHODS

Diclofenac sodium (DICS) and Tizanidine hydrochloride (TIZH) was obtained as gift sample from Lupin Research Park, Pune. Methocel- K4M and Avicel PH 101,102 was obtained as gift sample from Colorcon Pvt. Ltd, Goa. Chitosan was obtained as gift sample from Panacea Biotech, Mumbai. Guar gum, Potassium dihydrogen phosphate (AR), Methanol (AR), Methanol (HPLC grade), Water (HPLC grade) were given by SIRT college from company Merck India Ltd.,

Mumbai. sodium alginate, sodium hydroxide, magnesium stearate, xanthan gum, ethyl cellulose were given by SIRT college from Loba Chemie Pvt. Ltd., Mumbai. All other chemicals and reagents used were of "analytical reagents".

Micromeritic characterization of drug

Loose bulk density and Tapped bulk density: 10 gm sample was carefully introduced into a 25 mL graduated cylinder⁴. The volume occupied by the powder was recorded and bulk density then calculated and the cylinder was dropped at 2-second intervals onto a hard wood surface 100 times from a height of 1 inch.

$$D_f = M / V_p$$

$$D_o = M / V_p$$

Where,

D_f = Loose bulk density

M = Weight of samples in grams

V_p = Final volume of powder in cm^3

D_o = Tapped bulk density.

Compressibility Index and Hausner's ratio: The compressibility index and the Hausner ratio are determined by measuring both the bulk density and the tapped density of a powder.

Compressibility = (tapped- loose bulk density)/loose bulk density*100

Hausner's ratio = tapped density/loosed bulk density

Angle of repose

A funnel was fixed at a height approximately of 2-4 cm over the platform. The loose powder was slowly passed along the wall of funnel, till the cone of the powder formed.

$$\tan \theta = h / r$$

$$\theta = \tan^{-1} h / r$$

Where,

θ = Angle of repose, h = Height, r = Radius

UV-VIS spectrophotometric Method for DICS and TIZH

Selection of solvent Study of spectra and selection of analytical wavelengths: The solvent phosphate buffer pH 6.8 was used for the preparation. An amount equivalent to 10 mg of the reference standard DICS and TIZH was added to 100 mL volumetric flasks separately. DICS and TIZH was dissolved separately in around 50 mL Phosphate Buffer Saline (PBS) pH 6.8 in a 100 mL volumetric flask with vigorous shaking followed by ultrasonication for about 5 minutes. The volume was made up to the mark with the same solvent to obtain standard stock solutions of concentration, 100 $\mu g / mL$ of both drugs. By appropriate dilution of the standard stock solution, working standard solutions of suitable concentrations (10 $\mu g / mL$) of DICS and TIZH were prepared separately. The standard solutions were then scanned in the spectrum mode of the instrument from 400 nm to 200 nm to determine λ_{max} (wavelength maximum) for both DICS and TIZH.

Study of Beers-Lambert's Law

Preparation of standard stock solutions: Standard stock solutions (100 $\mu g / mL$) of DICS and TIZH were prepared separately. 10 mg of drug was dissolved in 50 mL of distilled water in 100 mL volumetric flask with shaking and then volume was made up to the mark with same solvent.

Preparation of standard calibration curves and selection of analytical concentration ranges: For DICS, appropriate

aliquots of standard stock solution of the drug were transferred to a series of 10 mL volumetric flasks. The volume was made up to the mark with PBS pH 6.8 to obtain working standard solutions of concentrations of 5, 10, 15, 20...35 $\mu g / mL$. TIZH appropriate aliquots of standard stock solution of the drug were transferred to a series of 10 mL volumetric flasks. The volume was made up to the mark with PBS pH 6.8 to obtain working standard solutions of concentrations of 3, 6, 9, 12, 15...21 $\mu g / mL$. Similarly, for The absorbances of three replicates of the working standard solutions of each concentration were measured at the selected analytical wavelengths. The standard calibration curves of absorbance vs. concentration were plotted.

Multicomponent detection analytical method

(Simultaneous Equation Method): In this method absorbances were measured at λ_{max} (λ_1 and λ_2) of both the drugs, i.e. DICS (10 $\mu g / mL$) and TIZH (10 $\mu g / mL$). Two equations were constructed based upon the fact that at λ_1 and λ_2 , the absorbance of the mixture is the sum of the individual absorbances of DICS and TIZH^{5,6}.

$$C_{DICS} = A_2 a_{y1} - A_1 a_{y2} / a_{x2} a_{y1} - a_{x1} a_{y2}$$

$$C_{TIZH} = A_1 a_{x2} - A_2 a_{x1} / a_{x2} a_{y1} - a_{x1} a_{y2}$$

Where, A_1 and A_2 are absorbance of mixture at λ_1 and λ_2 , a_{x1} and a_{x2} are absorptivities of DICS at λ_1 and λ_2 respectively. a_{y1} and a_{y2} are absorptivities of TIZH at λ_1 and λ_2 respectively and C_{Dico} and C_{Tiza} are concentrations of DICS and TIZH respectively.

Determination of solubility of DICS and TIZH: Saturation solubility of DICS and TIZH was determined in 0.1 N HCl, pH 1.2, pH 4.5 buffer and pH 6.8 phosphate buffer solutions. All media were prepared and excess quantity of DICS and TIZH was individually added to it and kept for shaking on mechanical shaker for 48 hrs. After 48 hrs of shaking, 1 mL of aliquot was taken out from each sample and filtered through whatman filter paper (45 μm). Filtrates were diluted with respective solution (i.e. 0.1 N HCl, pH 1.2, pH 4.5 buffer and pH 6.8 phosphate buffer). Absorbance was measured and solubility was determined for both the drugs.

Method Development by HPLC for DICS and TIZH

Selection of mobile phase: The criteria employed for selection of particular solvent system for the analysis was cost, time required for analysis, sensitivity of the assay and solvent noise for the analysis of DICS and TIZH from tablet formulation⁸. Various ratios of acetonitrile (ACN): water (HPLC grade) 25mM phosphate buffer pH 7 were tried to develop a sensitive and accurate method like;

1. ACN: Water (70: 30 v/v)

2. ACN: Water (50: 50 v/v)

Then, phosphate buffer pH 7 was used instead of water.

1. ACN: 25mM phosphate buffer pH 7 (70: 30 v/v)

2. ACN: 25mM phosphate buffer pH 7 (50: 50 v/v)

Preparation of standard stock solutions and Wavelength

1. Selection of analytical

Standard stock solutions (100 $\mu g / mL$) of DICS and TIZH were prepared separately. Dissolve 10 mg of drug in 100 mL of volumetric flask with 50 mL of acetonitrile: water (HPLC grade) (1:1 v/v) with shaking and then volume was made up to the mark with same solution⁸.

By appropriate dilution of the standard stock solution with mobile phase, various concentrations of DICS and TIZH were prepared separately. Their spectra were obtained using the double beam UV visible spectrophotometer.

Preparation of Standard Calibration curves of DICS and TIZH by HPLC Method

Chromatographic conditions

The chromatographic column used was a reverse phase 4.6 μ 250 mm Hypersil C₁₈ HPLC column with 5 μ m (particles) packing. The column and the HPLC system were kept at ambient conditions⁸. The mobile phase was ACN: Phosphate buffer pH 7.0 (50:50 v/v) delivered at a flow rate of 1.0 mL/min. The injection volume was 25 μ L. Elute was analyzed by a UV detector set at 220 nm. For preparation of standard calibration curve, appropriate aliquots were pipette out from stock solutions into a series of 10 mL volumetric flasks. The volume was made upto the mark with mobile phase to obtain a set of solutions of DICS having concentration range 2-10 μ g/mL each and 2.5-12.5 μ g/mL for TIZH. Triplicate dilutions of each concentration of drug were prepared. From these triplicate solutions, 25 μ L injection of each concentration of drug was injected into the HPLC system. Evaluation of both drugs was performed with the UV detector set at 220 nm. Peak area was recorded and working calibration curves were plotted separately with peak area Vs the respective concentration of DICS and TIZH.

Formulation Development: All of the formulations contained 100 mg DICS, 6.86 mg of TIZH, 1% (w/w) magnesium stearate, microcrystalline cellulose (MCC) and different amounts of various polymers. The composition of various formulations is listed in Table 1

Preparation of Matrix Tablets: Various formulations of tablets were prepared as shown in Table 14. The drug powder and other ingredients were passed through an 80 mesh sieve before mixing. In order to keep the volume and surface area of tablets relatively constant, the final weight of each tablet was maintained at 300 mg. All of the formulations contained 100 mg of DICS, 6.86 mg of TIZH (6.86 mg of tizanidine hydrochloride equivalent to 6 mg of tizanidine), 1% (w/w) magnesium stearate and different amounts of various polymers and Avicel-102. The composition of various formulations is listed in Table 14. DICS, TIZH and other ingredients were weighed and the mixture was then blended with magnesium stearate (1% w/w) as lubricant in a polybag, and then compressed into tablets. All tablets were prepared using six station rotary tablet machine (GMC Mumbai) equipped with standard concave punches of 9-mm diameter.

Evaluation parameters for table

Hardness: Although hardness test is not an official, tablet should have sufficient handling during packing and transportation^{6,7}. Hardness of tablet was measured using Monsanto hardness tester. The hardness of 6 tablets, from each batch was determined and mean hardness was taken into account, which was expressed in kg/cm².

Weight variation test: Weigh 20 tablets individually, calculating the average weight and compare the individual tablet weight with respect to the USP weight variation test

Friability: Friability test is performed to assess the effect of

friction and shocks, which may often cause tablet to chip, cap or break. Roche friabilator was used for the purpose.

The percentage friability was measured using the formula,

$$\% F = \{1 - (W_0/W)\} \times 100 \text{ ----- (25)}$$

Where,

% F = friability in percentage, W₀ = Initial weight of tablet
W = weight of tablets after revolution

Thickness: The thickness of the tablet was measured using vernier caliper. Thickness of five tablets from each batch was measured and mean was calculated

Content uniformity: For this at least 30 tablets were randomly selected. Out of 30 tablets, 10 tablets were crushed into fine powder and assayed individually.

In vitro dissolution studies: The *in vitro* dissolution studies were performed using USP-22 type-II dissolution apparatus at 50 rpm. The dissolution medium consisted of phosphate buffer solution pH 6.8 for 12 hours (900 mL), maintained at 37°C \pm 0.5°C. An aliquot (10 mL) was withdrawn at specific time intervals and drug content was determined by UV-visible spectrophotometer (UV-1700- Shimadzu Japan) at 276.2 nm and at 320 nm for DICS and TIZH respectively by using simultaneous equation method. At each time of withdrawal, 10 mL of fresh corresponding dissolution medium was replaced into the dissolution flask. It was made clear that none of the ingredients used in the matrix formulations interfered with the assay. The release studies were conducted in triplicate. Table 15 shows the parameter of dissolution studies.

Matrix integrity: Matrix integrity was observed throughout *in vitro* dissolution studies and the swollen mass of the tablets whether remains intact or not was checked.

Dissolution kinetic study: Various mathematical models like; Zero-order model, First-order model, Higuchi (Matrix) model, Hixson and Crowell cube-root equation and Korsmeyer-Peppas Model were evaluated with respect to the dissolution profiles of the optimised formulations of HPMC K4M and guar gum. PCP disso software was used to fit models to dissolution profiles^{8,9}.

Stability studies: The stability of the active component must be major criteria in determining their acceptance or rejection. During the stability studies the product is exposed to normal conditions of temperature and humidity. However, the studies will take a longer time and hence it would be convenient to carry out the accelerated stability studies where the product is stored under extreme conditions of temperature.

RESULTS AND DISCUSSION

Micromeritic characterization of drug: Table 2 shows the relationship between % compressibility and flow property of powder. From micromeritic characteristics study it was found that both the DICS and TIZH have good flow properties.

UV-VIS spectrophotometric Method for DICS and TIZH: UV spectrum for DICS and TIZH are shown in Figure 1 and 2 respectively.

Study of Beers-Lambert's Law: calibration curve for DICS: The calibration curve for DICS and TIZN in PBS pH 6.8 is shown in Figure 3 and 4 and Table no 3,4. The graph of absorbance vs. concentration for DICS was found to be linear

in the concentration range of 5-35 $\mu\text{g/ml}$ and 3-21 $\mu\text{g/ml}$ at 276.2 nm and 320 nm. The r^2 of the calibration curve was found to be 0.999.

Multicomponent detection for DICS and TIZH (Simultaneous Equation Method): In this method absorbances were measured at λ_{max} (λ_1 and λ_2) of both the drugs; i.e. diclofenac at λ_{max} of 276.2 nm and tizanidine at λ_{max} of 320 nm. Absorbance of DICS and TIZN was found to be 0.4849 and 0.07465 at 276.2nm and at 320 nm 0.01035 and 0.794. Figure 5 shows the overlay spectra of DICS and TIZH.

Determination of solubility: The solubility data for DICS and TIZH as observed in 0.1 N HCl and buffers of pH values 4.5 and 6.8 was found to be 0.069, 3.803 and 18.9

HPLC method development

Calibration curve of diclofenac sodium and tizanidine hydrochloride by HPLC

The chromatogram of pure **diclofenac sodium and tizanidine hydrochloride** at concentration 10 $\mu\text{g/ml}$ and 2 $\mu\text{g/ml}$. The standard calibration curve and table for DICS and TIZH is shown Figure 6 and 7, Table 5 and 6 respectively. A linear correlation was found between area under the curve and concentration in the ranges 6 to 16 $\mu\text{g/ml}$ and 2 to 12 $\mu\text{g/ml}$. The retention time was observed as 9.15 min and 5.66 min. The r^2 of calibration curve was found to be 0.998 and 0.996.

Evaluation of tablets

Hardness of tablets of each formulation was measured and was found in the range of 5-8 kg/cm^2 . Average weight of the tablet was found to be 300 ± 3 mg for all formulations. Percentage weight loss of the tablets of each formulation was measured and was found to be less than 1% for all the formulations. Diameter of formulations was found to be 9 ± 0.05 mm. Thickness was found to be 5 ± 0.2 mm for all the formulations. The content uniformity for all tablet formulations was found to be between 98.80 % to 100.40 % for DICS and 98.70 % to 100.20 % for TIZH. All parameter were shown on table 7

Matrix integrity

Integrity of a tablet matrices were studied at time interval of 1, 2, 4, 6, 8, and 12hr by visual observation. Matrices of tablets were found to have good integrity till the end of 12 hr. dissolution study, and as tablet matrices got eroded at controlled rate it was able to release both the drugs in controlled manner.

Dissolution kinetic study

Kinetics treatment

Table 8 shows the Kinetics treatment for the optimized formulations. From drug release kinetic model study, it was found that the **matrix (Higuchi) model** was best fitted for the optimised formulation F1 and F11, for both the drugs i.e. DICS and TIZH. From the regression value (R^2) it was found that Higuchi square root model was best fitted for both the formulations F1 and F11.

Stability study

Formulation F1 and F11 were kept for stability study, tablets were packed in PVC -PVDC coated aluminum - aluminum strip pack of 10 tablets and were kept at 45°C and 75% RH for 3 months. These formulations were evaluated for following parameters after stability study.

CONCLUSION

The prepared tablets were evaluated for various physical parameters of tablet and *in vitro* drug release. It was found that the concentration and type of polymer influences the release and compression characteristics of the sustained release tablets. Increase in concentration of polymer leads to decrease in release rate of both drugs. It was also found that particle size of drug also has considerable effect on drug release from formulation; as particle size decreased drug release increased. matrix systems developed were able to deliver the drugs by matrix (Higuchi) drug release model. This was achieved by a simple strategy of incorporating DICS and TIZH together in a matrix system of HPLC K4M by wet granulation method. This dosage form thus designed would be ideal for patients simultaneously suffering from muscle spasm associated with analgesia and inflammation and where both the drugs would be needed in a sustained manner, but being released together from a single unit dosage form.

ACKNOWLEDGEMENT

The authors are very much thankful to surendra kumar jain Director, SIRT College of Pharmacy BHOPAL, for his valuable support and providing necessary facilities to carry out the research work.

REFERENCES

1. Chien YW., Novel drug delivery system, Marcel dekker Inc, New York, 1992;2:139-140.
2. Lachman L, Liberman HA, Kanig JL., The theory and practice of industrial pharmacy, Varghese publishing house India, 1987, 3rd.: 443-453.
3. Wang XCF, Yonezawa Y, Sunada H., Preparation and evaluation of combination tablet containing incompatible active ingredients, Chem. Pharm. Bull., 2003; 51: 77-72.
4. Kumar RS, Karthikeyan C, Moorthy N.S.H.N, Trivedi P., New spectrophotometric methods applied to the simultaneous determination of diclofenac potassium and tizanidine, Indian J pharmSci., 2006;68(3): 317-322.
5. Subhramanian G, Musmade P, Agarwal S, Udupa N., Simultaneous RP-HPLC estimation of tizanidine, diclofenac, paracetamol in tablets, Indian J pharmSci, 2004; 694-696.
6. ICH Q2A, Text on validation of analytical procedures international conference on harmonization, Geneva. 1994; 1-5.
7. ICH Q2B, Validation of analytical procedures, methodology international conference on harmonization, Geneva. 1996; 1-8.
8. Dressman B, Amidon GL, Reppas C, Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm Res., 1998; 15 (1): 11-22.
9. Costo P, Lobo J, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 2001;13 (2): 123-133.

Table 1a: Composition of formulations

Formulation	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10
DICS	100	100	100	100	100	100	100	100	100	100
TIZH	6.86	6.86	6.86	6.86	6.86	6.86	6.86	6.86	6.86	6.86
HPMC K4M	30	45	60	90	120	150	-	-	-	-
HPMCK 15 M	-	-	-	-	-	-	90	120	150	-
HPMC K100M	-	-	-	-	-	-	-	-	-	90
AVICEL 102	160.14	145.14	130.14	100.14	70.14	40.14	100.14	70.14	40.14	100.14
Mg. sterate	3	3	3	3	3	3	3	3	3	3
Total weight	300	300	300	300	300	300	300	300	300	300

Table 1b: Composition of formulations

Formulation	F11	F12	F13	F14	F15	F16	F17	F18	F19	F20
DICS	100	100	100	100	100	100	100	100	100	100
TIZH	6.86	6.86	6.86	6.86	6.86	6.86	6.86	6.86	6.86	6.86
Guar Gum	15	30	90	200	30	-	-	-	-	-
Chitosan	-	-	-	-	-	60	60	30	-	-
Sod. Alginate	3	3	3	3	3	60	30	90	-	-
Xanthan Gum	-	-	-	-	-	-	-	-	30	60
Ethyl Cellulose	-	-	-	-	-	-	-	-	30	60
AVICEL 102	-	-	-	-	160.14	70.14	100.14	100.14	130.14	70.14
AVICEL 101	175.14	160.14	100.14	100.14	-	-	-	-	-	-
Mg. sterate	3	3	3	3	3	3	3	3	3	3
Total weight	300	300	300	300	300	300	300	300	300	300

Table no 2: Micromerite characterization of drugs

Sr. No.	Parameters	Result of DICS	Result of TIZH
1	Loose bulk density	0.43±0.03g/cm ³	0.51±0.04g/cm ³
2	Tapped density	0.49±0.04g/cm ³	0.58±0.06g/cm ³
3	Carr's Index	13.95±0.05 %	13.72±0.03 %
4	Hausner's ratio	1.139	1.137
5	Angle of Repose	30° 18'	28° 34'




Figure 1: UV spectra of DICS (10µg/mL) in PBS pH 6.8 (λ_{max} =276.2nm)




Figure 2: UV spectra of TIZH (10µg/mL) in PBS pH 6.8 (λ_{max} =320nm)




Figure 3: Calibration Curve of DICS




Figure 4: Calibration Curve of TIZH




Figure 5: Overlay UV spectra of DICS and TIZH in PBS pH 6.8




Figure 6: Calibration curve of DICS




Figure 7: Calibration curve of TIZH




Figure 8: Chromatogram of DICS




Figure 9 Chromatogram Of TIZH

Table 3: Concentration and Absorbance values for DICS and TIZH in PBS pH 6.8

Sl. No	Concentration	Absorbance at 276.2nm	Concentration	Absorbance at 276.2nm
	DICS		TIZN	
1	0	0.1645	0	0
2	5	0.2917	3	0.1393
3	10	0.4469	6	0.29018
4	15	0.6141	9	0.41925
5	20	0.7359	12	0.5975
6	25	0.8553	15	0.747
7	30	1.015	18	0.881
R²	0.999		0.999	
Slope	34.7718		19.62316	
Intercept	-0.4222		0.310103	

Table 4: Concentration and Area Value for DICS and TIZN

Sl. No	Concentration	AUC 220.0nm	Concentration	AUC 220.0nm
	DICS		TIZN	
1	0	0	0	0
2	6	170493	2	113455
3	8	233270	4	197389
4	10	285990	6	286789
5	12	338344	8	370610
6	14	384983	10	449783
7	16	438985	12	5.9245
R²	0.998		0.997	
Slope	27403		43993	
Intercept	6207		15652	

Table 5: Evaluation Parameter of Tablets

Formulations	Hardness (kg/cm ²)*	Thickness (mm)	Weight Variation (mg)	Friability (%)	Drug Content	
					DICS	TIZH
F1	6-7	5±0.10	300±2	0.60±0.02	99.20±0.20	98.90±0.20

F2	6-7	5±0.10	300±2	0.60±0.05	99.30±0.10	99.40±0.20
F3	6-7	5±0.10	300±1	0.60±0.05	98.90±0.20	99.30±0.30
F4	6-7	5±0.20	300±2	0.50±0.06	100.20±.20	98.70±.30
F5	6-7	5±0.20	300±1	0.50±0.06	99.60±0.30	100.20±.20
F6	6-7	5±0.20	300±2	0.46±0.04	99.20±0.20	99.80±0.40
F7	6-7	5±0.10	300±1	0.41±0.03	99.45±0.20	100.1±0.10
F8	6-7	5±0.20	300±2	0.50±0.06	98.80±0.30	98.70±0.30
F9	6-7	5±0.20	300±2	0.66±0.04	99.40±0.40	98.80±0.20
F10	6-7	5±0.10	300±1	0.61±0.05	99.70±0.10	99.20±0.10
F11	7-8	5±0.10	300±2	0.56±0.03	100.1±0.10	99.90±0.20
F12	7-8	5±0.20	300±3	0.46±0.03	99.30±0.20	99.70±0.20
F13	7-8	5±0.10	300±1	0.51±0.06	101.1±0.10	101.2±0.10
F14	5-6	5±0.10	300±2	0.54±0.04	100.4±0.10	99.60±0.10
F15	6-7	5±0.10	300±3	0.41±0.04	99.20±0.40	98.90±0.20

Table 6: % cumulative release for 12 hours

TIME hr	F1		F11	
	DICS	TIZH	DICS	TIZH
0.5	18.38	20.22	19.1	20.1
1	27.34	27.55	27.42	27.89
2	42.52	44.22	43.09	45.34
3	51.22	52.23	50.98	51.65
4	60.35	58.01	61.09	57.97
6	72.32	69.34	72.16	69.52
8	81.42	79.67	81.34	78.9
10	90.56	88.34	90.37	88.28
12	99.23	97.04	98.99	97.34




Figure 10: Dissolution profile of DICS and TIZH using HPMC K4M for 12 hrs




Figure:11 Dissolution profile of DICS and TIZH using Guar gum polymer 12 hrs

Source of support: Nil, Conflict of interest: None Declared